Skip to main content

Covid Cure: Is Plasma Therapy the big find of the Century

A new plasma therapy along with a negative ion therapy claims to have cured Covid 19 patients within a short span of forty-eight hours. How far are we from nailing the solution in India

By Namrata Kohli

It’s called the Hyperion Plasma Treatment and has been administered successfully to over three thousand patients across China, Germany and UAE. This new treatment is proving to be far more effective than the conventional plasma treatment and is invented by a team of scientists from European Medical Association (EMA), together with Redcliffe Lifesciences and Sapio Analytics.

For some time now, doctors have been trying every anti-viral drug and antibiotic combination to treat the Coronavirus infected patients. They then moved towards a non-drug plasma therapy which simply put, uses the serum of plasma from a recovered individual which is then injected into the blood stream of an infected individual. Plasma therapy is nothing new, says Prof. Dr Amina Ather, part of the inventor team- "In Germany, where people do not get any vaccination, they get injected with plasma whenever they have severe infection. But we have combined the widely accepted concept of plasma treatment, with adjuvant negative ion therapy using a proprietary ionizer device and this combination seems to be working.”

The inventor team under the umbrella of EMA, comprises Dr. Ahmad Abdul aziz Al Jaziri from UAE along with Prof. Dr Amina Ather and Dr. Nayak S.V as lead research and clinical leader. According to r Jaziri, the lead inventor- “We have innovated an accessible treatment of COVID-19 which has already been applied in China and Germany with successful results. It is proving to be ten times more effective than conventional plasma therapy. The recovery rate of severe and acute patients is less than 48 hours.” Dr Jaziri has previously invented some medical devices, like for removing abdominal tumors in a non invasive way and clip applicator which was patented in Germany.

The group is in the process of seeking approvals from ICMR and other authorities in order to start off clinical trials in India. Science and technology have larger responsibility now than ever before to come out with solution, says Dheeraj Jain, Founder, Redcliffe Life Sciences who adds that its still early days to comment on the pricing of this treatment. 

My Take:
We always thought that a doctor, a scientist had all the solutions. But this coronavirus has baffled the entire scientific/medical fraternity who have been struggling with every solution under the sun - from “trial and error” and "calculated risks" to a bouquet of drug and non-drug therapies. With more time, experience and as the research on the virus matures, we are slowly but surely inching towards the solution.
What will this cost to a layperson? How soon will this method be applicable? are few questions that need to be answered. Also as studies establish that the virus will continue to stay within the human body for six months, is this therapy to be used for second attacks and will it be successful in combating subsequent attack.
In this humanity's war against Corona, the least we can do to help the health/medical fraternity/frontline soldiers who are at the forefront of this battle, is try and stay safe and not increase the numbers. Let's stay united and stay indoors.

Comments

  1. Thanks for this amazing article. I loved it haute her health.

    ReplyDelete
  2. I admire this article for the well-researched content and excellent wording. I got so involved in this material that I couldn’t stop reading. I am impressed with your work and skill. Thank you so much.
    второе медицинское мнение

    ReplyDelete
  3. https://www.discogs.com/user/Learnwithshikha

    ReplyDelete

Post a Comment

Popular posts from this blog

Telemedicine to the aid of home-bound patients in the time of Covid-19

Telemedicine in covid-19 times: You can get to the doctor almost anytime, anywhere, be it on your screen, via voice or plain text for a lower price than in-person consult Namrata Kohli   |   New Delhi Telehealth is bridging the gap between patient and physicians. The physician can now virtually visit the stay-at-home patient and heal from a distance Telemedicine in covid-19 times:  When 37-year-old Priyanka was down with fever and dry cough, she decided to consult a doctor over a WhatsApp call before giving her blood sample for an RT-PCR test. Based on her symptoms, the physician alerted her that it wasn't a mild Covid infection but a moderate one. His diagnosis was confirmed when the test report showed a viral load count of 20. “The massive benefits of telemedicine became evident during the pandemic,” says Priyanka’s doctor, New Delhi-based consultant physician Dr Arvind Kumar. “Everything is about time and if my patients have complications late at ni...

WWW Redefined: Wealth in Women’s Wallets

  By Namrata Kohli Why do women not make money or take money seriously? How many women in India have a concept of “my money” as different from family savings. Rather than a pragmatic view of money being a means to a good life, most women have an emotional relationship with money- one which is tied to guilt, control or sacrifice. Her money is still considered “supplemental” and as a bonus and never as priority. Even in cases where she is earning, there is a hesitation to invest. Women merely save, which is actually negative return- if you saved Rs 100 then next year its value is merely Rs 90 if you factor in inflation of 8-10%. Financial freedom needs to be a goal and not just a byproduct. Last week, I was a speaker at an event on "Financial Empowerment of Women- Bridging The Gender Wealth Gap" at the TalentNomics India’s 9th Global Annual Conference, in partnership with Konrad Adenauer Stiftung’s Regional Economic Programme Asia (SOPAS). The event titled "Restoring t...

As Indian art gets famous, a great chance to diversify your portfolio

  Do you look at Art as an asset, emotion or legacy? Know the reasons why you want to buy art With record-breaking sales, Indian Art finds its voice—and value—at home and abroad. From Husain to the next Gen, Indian Art enters a golden phase By Namrata Kohli  There is a new found buoyancy in the Indian art market and excitement amongst artists and art collectors in India. A landmark event was the sale of Maqbool Fida Husain’s 1954 painting  Untitled (Gram Yatra)  for $13.7 million, (about 118 crore rupees),  making it the most expensive work of Modern Indian art ever sold in a public auction. According to Roshini Vadehra, Director, Vadehra Art Gallery and Trustee, Foundation for Indian Contemporary Art, “Overall, South Asian art is having a great moment, with mostly the domestic market driving the scene and people buying across generations and mediums. The masters are of course at the top end because of the rarity of the works. But the collector today is well edu...